In terms of valuation, Vincerx Pharma Inc’s market capitalization stands at $3.62 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market ...

Vincerx Pharma Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -84.03%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...

On 3 rd June, financial analyst Geoffrey Porges of SVB Leerink predicted that remdesivir would deliver revenues approaching $2 billion in 2020, rising to $7.7 billion by 2022. These figures are ...

Roche Holding AG Akt 0.56% CHF214.52B ...

Wednesday after the company’s fourth-quarter print. Stryker reported quarterly earnings of $4.01 per share, which beat the ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study with Elevidys. The firm views these topline results ...

Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.61 EPS, FY2028 earnings at $4.55 EPS and FY2029 ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $70.37 ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...